Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Recruiting now
Conditions studied: Retinoblastoma
In brief
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.
Key facts
- Study ID
- NCT04425434
- Run by
- French Africa Pediatric Oncology Group
- People needed
- 3000
- Starts
- 2020-11-01
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2026-03-02
Who can join
Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Unilateral intraocular Retinoblastoma (RB)
- Unilateral extraocular intraorbital (RB)
- Bilateral intraocular (RB)
- bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.
You may not qualify if…
- Externalized tumor mass
- massive extension to optic nerve up to optical channeltumor
- intracranial extension leptomeninges
- cerebral parenchyma
- extension to regional lymph nodes and/or remote metastases.
- cerebrospinal fluid involvement.
- Trilateral RB
- Incapacity to followed the whole treatement.
Where it is running
- Hopital Yalgado Ouedraogo — Ouagadougou, Burkina Faso (enrolling)
- CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (enrolling)
- CUK (Cliniques Universitaires de Kinshasa) — Kinshasa, Kinshasa City, Democratic Republic of the Congo (enrolling)
- Cliniques Universitaires de Lubumbashi (CUL) — Lubumbashi, Democratic Republic of the Congo (enrolling)
- HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona — Antananarivo, Ampefiloha, Madagascar (enrolling)
- CHU Gabriel Touré (HGT) — Bamako, Mali (enrolling)
- Hôpital Aristide Le Dantec, — Dakar, Senegal (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.